Why it matters now
The pharmaceutical industry is on the cusp of a significant wave of patent expirations for blockbuster biologic drugs. This 'patent cliff' presents immense opportunities for biosimilar manufacturers to enter the market and for healthcare systems to achieve substantial cost savings. For originator companies, it necessitates robust lifecycle management and pipeline diversification. Understanding which biologics are next to face biosimilar competition is critical for market forecasting, R&D investment, and competitive strategy.
Who is exposed
Originator biologic manufacturers face significant revenue erosion as biosimilars enter the market, impacting profitability and R&D budgets. Generic drug companies see substantial market entry opportunities and potential for rapid growth. Healthcare payers stand to gain from reduced drug costs, improving budget management. Pharmacy benefit managers will adjust formularies to incorporate biosimilars, influencing patient access and prescribing patterns.
Most relevant for: Head of Portfolio Strategy, Chief Commercial Officer, Investor Relations
What this Viewpoint covers
- Which top-selling biologic drugs are projected to lose exclusivity in the specified period?
- What are the estimated market values of these biologics at the time of exclusivity loss?
- Which biosimilar developers are most advanced in developing competing products?
- What are the key patent expiry dates and regulatory hurdles for these biologics?
- How might the entry of biosimilars impact pricing and market share for these drugs?
Signals to watch
- Announcements of new biosimilar clinical trials or regulatory filings.
- Patent litigation outcomes for key biologic drugs.
- Changes in healthcare payer policies regarding biosimilar adoption.
- Reports on R&D pipelines of major biosimilar manufacturers.
Decisions it supports
- Prioritize R&D investments for new biologic pipeline assets.
- Develop market entry strategies for biosimilar products.
- Optimize formulary management and drug procurement strategies.
How it is built
Prepared after your order from dated public sources - such as biopharmaceuticals filings and announcements, regulatory records, trials, patents and trade data, where relevant - and our market model. Reported facts are cited, estimates are labelled and our assessment is marked as such, following our research method. You receive our verdict, the evidence, who is exposed, the signals to watch and recommended actions, within 24 hours.
Questions
Why is understanding the upcoming biosimilar wave important for my business?
The impending loss of exclusivity for major biologics will reshape the pharmaceutical landscape. For originators, it's about mitigating revenue erosion; for biosimilar makers, it's about seizing market opportunities. This insight is crucial for strategic planning, R&D investment, and competitive positioning to navigate this significant market shift effectively.
What kind of biologics are typically affected by biosimilar competition?
Biologics are large, complex molecules, often antibodies or proteins, used to treat conditions like autoimmune diseases, cancer, and diabetes. The ones facing biosimilar competition are typically those with high sales volumes and established clinical use, where the cost savings from biosimilar entry can be substantial for healthcare systems globally.
How can this Viewpoint help my R&D and portfolio strategy?
This Viewpoint helps you identify which existing products will face new competition, allowing you to adjust lifecycle management strategies. For R&D, it highlights therapeutic areas where new biologics are needed to fill potential revenue gaps, guiding investment in innovative pipeline assets and ensuring a sustainable product portfolio for the future.